SOLVING THE TOUGHEST TREATMENT CHALLENGES ACROSS AUTOIMMUNE DISEASES
Oblenio Bio is pursuing broad immune reset as a transformative therapy for refractory autoimmune diseases through our LBL-051 T-cell engager. Specifically engineered for autoimmune patients, our tri-specific unites validated targets BCMA, CD19 and CD3 to safely and completely deplete B-cells and plasma cells to achieve long-term drug-free remission. Led by proven drug developers and industry leaders, we are singularly focused on LBL-051’s groundbreaking clinical development program to rapidly establish it as a life-changing treatment for the vast number of patients who endure severe autoimmune disease without relief.
OUR APPROACH
BCMAxCD19xCD3 Tri-specific Targeting
We are at the forefront of applying novel science in T-cell engager antibodies to develop a potentially robust and durable therapeutic approach for autoimmune diseases.
LBL-051 is one of the most advanced tri-specific T-cell engagers in development that targets BCMA, CD19 and CD3. Engineered specifically for autoimmune disease application, the multi-targeting functionality of LBL-051 sets it apart, enabling it to deplete pathological B-cell populations that are implicated in a wide spectrum of autoimmune diseases.
Resetting the Immune System
LBL-051 is engineered to elevate the demonstrated clinical potential of BCMA-, CD19- and CD3-targeted therapies to address difficult treatment challenges in autoimmune diseases, including lasting drug-free remissions. LBL-051 is designed to deplete the entire lineage of pathological B-cells and achieve immune reset, potentially delivering superior efficacy and durability compared with single-target or bispecific options.
OUR FOCUS
Raising the Bar on T-Cell Engagers
Our team is focused on unlocking the full potential of BCMA, CD19 and CD3 targeting as a paradigm-shifting treatment approach across a broad range of autoimmune diseases.
NEWS
PUBLICATIONS
Treatment with LBL-051-S3, a CD3/CD19/BCMA trispecific antibody, leads to a complete loss of plasma cells and B cells with minimal cytokine release in non-human primates
Hertz A, Daige C, Wong S, et. al.
Poster presentation at The European Alliance of Associations for Rheumatology (EULAR) Annual Meeting. June 2026.
CONTACT US
For general, corporate or business development inquiries, please contact us.
Email: info@obleniobio.com
4 Maguire Road, Lexington, MA 02421